Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Chimerix turns $39m into $935m
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
T-cell engagement with a difference
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
Hello BridgeBio, farewell Syros and Achilles
One step forward, two steps back for biotech.
Protagonist Verifies Takeda’s interest
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
A pivotal push from BeiGene
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Oric looks over its shoulder
Tough equity markets as well as competitor developments prompt a narrowed focus.
The month ahead: March's upcoming events
Another SERD catalyst and the son of Darzalex take centre stage.
